Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non–muscle-Invasive Bladder Cancer
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q2Scopus Q1KCI Q1
- 저널
- Cancer Research and Treatment58(2) · pp.591 · 2026
- 피인용
- Web of Science 1Scopus 1KCI 0
- FWCI (Scopus)
- 1.83
- JCR IF
- JCR 2024 3.8
- ISSN
- 1598-2998
저자
- 이혜원제1저자Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
- 정의현Natl Canc Ctr, Ctr Urol Canc, Dept Urol, 323 Ilsan Ro, Goyang 10408, South Korea
- 김경환Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Urol, Coll Med, Busan, South Korea
- 하홍구Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Urol, Coll Med, Busan, South Korea
- 오종진Seoul Natl Univ, Bundang Hosp, Dept Urol, Coll Med, Seongnam, South Korea
- 강석호Korea Univ, Coll Med, Dept Urol, Anam Hosp, Seoul, South Korea
- 정승환Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
- 육현동Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
- 허지은Yonsei Univ, Urol Sci Inst, Dept Urol, Coll Med, Seoul, South Korea
- 함원식Yonsei Univ, Urol Sci Inst, Dept Urol, Coll Med, Seoul, South Korea
- 황의창Chonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
- 정승일Chonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
- 송완Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
- 임범진Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
- 홍범식Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
- 정병창Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
- 서호경교신저자Natl Canc Ctr, Ctr Urol Canc, Dept Urol, 323 Ilsan Ro, Goyang 10408, South Korea
초록
PurposeThis study aimed to report the real-world outcomes of intravesical gemcitabine for bacillus Calmette–Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (HR-NMIBC) in Korean patients who were unable or unwilling to undergo radical cystectomy (RC).Materials and MethodsThis retrospective study included 131 patients (median age, 69 years; 88.5% men) treated with intravesical gemcitabine for BCG-unresponsive HR-NMIBC at nine centers between May 2019 and April 2022. The primary endpoint was 1-year recurrence-free survival (RFS). The secondary endpoints included factors influencing RFS, progression-free survival (PFS), cystectomy- free survival, cancer-specific survival (CSS), overall survival (OS), and safety. Survival analysis was performed using the Kaplan-Meier method, and risk factors for recurrence were assessed using Cox regression models.ResultsPatients were followed up for a median duration of 25 months, with carcinoma in situ (CIS) in 41.9% of the patients. The 1-year and 2-year RFS rates were 68% and 42%, while the 1-year and 2-year PFS rates were 87% and 77%, respectively. No significant factors influencing RFS were identified. Seventeen patients underwent RC during a median follow-up of 16 months, with the condition in three patients progressing to muscle-invasive disease on final pathological analysis. The 2-year CSS and OS rates were 98% and 97%, respectively. Intravesical gemcitabine was well-tolerated, with only seven patients (5.3%) unable to complete the full induction course.ConclusionOur research highlights the potential of intravesical gemcitabine as a viable bladder-sparing treatment option for BCG-unresponsive HR-NMIBC, providing real-world evidence on its safety, efficacy, and tolerability.
키워드
TherapeuticsNon-muscle invasive bladder neoplasmsBacillus Calmette–GuérinFailureOrganization and administrationIntravesical administrationGemcitabineOrgan preservation
식별자
- Scopus EID
- 2-s2.0-105035841246
- WoS UID
- 001743756600021
- KCI
- ART003325921



로그인
연구물 목록으로